Rotigotine for the treatment of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 6, Issue 9, 2006, Pages 1275-1282

  Morgan, John C ^a,b   Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonist; N 0437; N 0923; Parkinson's disease; Rotigotine; Transdermal patch

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOLINE DERIVATIVE; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

APPLICATION SITE REACTION; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG LEGISLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; NAUSEA; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRURITUS; REVIEW; SKIN MANIFESTATION; SOMNOLENCE; VOMITING;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; HUMANS; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 33750079581     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.9.1275     Document Type: Review

References (57)

1. DeStefano AL, Lew MF, Golbe LI et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet. 70(5), 1089-1095 (2002).
2. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52(6), 1214-1220 (1999).
3. Huse DM, Schulman K, Orsini L et al. Burden of illness in Parkinson's disease. Mov. Disord. 20(11), 1449-1454 (2005).
4. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276(7), 374-379 (1967). •• Seminal paper demonstrating the efficacy of levodopa in Parkinson's disease (PD).
5. Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitonel and pleural fibrosis induced by pergolide. J. Neurol. Neurosurg. Psychiatr. 66(1), 79-81 (1999).
6. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc. 77(12), 1280-1286 (2002).
7. Management of Parkinson's disease: an evidence-based review. Mov. Disord. 17(Suppl. 4), S1-S166 (2002). • Evidence-based review of PD pharmacotherapy.
8. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58(1), 11-17 (2002). • Evidence-based review of PD pharmacotherapy.
9. Eisler T, Eng N, Plotkin C, Calne DB. Absorption of levodopa after rectal administration. Neurology 31(2), 215-217 (1981).
10. Nausieda PA, Pfeiffer RF, Tagliati M et al. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin. Ther. 27(1), 58-63 (2005).
11. Iyer SS, Morgan JC, Sethi KD. Absorption of orally-disintegrating carbidopa-levodopa requires intact small bowel function. Neurology 65(9), 1507 (2005).
12. Clarke A, Brewer F, Johnson ES et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm. 110(11), 1241-1255 (2003).
13. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19(4), 426-432 (2004).
14. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 328(3), 176-183 (1993).
15. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol. 59(12), 1937-1943 (2002).
16. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62(2), 241-248 (2005).
17. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463), 947-954 (2005).
18. Beaulieu M, Itoh Y, Tepper P et al. N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists. Eur. J. Pharmacol. 105(1-2), 15-21 (1984).
19. Timmerman W, Westerink BH, De Vries JB, Tepper PG, Horn AS. Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers on N-0437. Eur. J. Pharmacol. 162(1), 143-150 (1989).
20. Van der Weide J, Tendijck ME, Tepper PF, De Vries JB, Dubocovich ML, Horn AS. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and post-synaptic dopamine receptors. Eur. J. Pharmacol. 146(2-3), 319-326 (1988).
21. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65(2 Suppl. 1), S3-S5 (2005). • Excellent summary of preclinical data on rotigotine.
22. Belluzzi JD, Domino EF, May JM, Bankiewicz KF, McAfee DA. N-0923, a selective D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. 9(2), 147-154 (1994).
23. Mucke HA. Rotigotine Schwarz Pharma. IDrugs 6(9), 894-899 (2003).
24. Lebsanft HB, Scheller DKA, Heindl M et al. Effect of continuous administration of rotigotine in a rat model of dyskinesia. Mov. Disord. 20(Suppl. 10), S89 (2005).
25. Schneider JC, McLaughlin WW, Roeltgen DP. Anti-Parkinson effects of the selective dopamine D-2 agonist N-0923 in hemi-Parkinsonian monkeys. Neurology 42(4 Suppl. 3), 443 (1992).
26. Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation. Ann. Neurol. 56(Suppl. 8), S54 (2004).
27. Stichel CC, Scheller DKA. Rotigotine prevents neurodegeneration in a mouse model of Parkinson's disease. 9th Congress of the European Federation of Neurological Societies, Athens, Greece (2005) (Abstract 250).
28. Swart PJ, de Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 47(8), 613-615 (1992).
29. Swart PJ, de Zeeuw RA. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienlethylamino)-5-hydroxyteralin in freely moving rats. J. Pharm. Sci. 82(2), 200-203 (1993).
30. Calabrese VP, Lloyd KA, Brancazio P et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord. 13(5), 768-774 (1998).
31. Metman LV, Gillespie M, Farmer C et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol. 24(3), 163-169 (2001).
32. Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol. 28(3), 106-110 (2005).
33. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function. J. Clin. Pharmacol. 45(9), 1091 (2005) (Abstract 102).
34. Watts RL, Wendt RL, Nausied B et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov. Disord. 19(Suppl. 9), S258 (2004).
35. Braun M, Cawello W, Poole K et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. 9th Congress of the European Federation of Neurological Societies, Athens, Greece (2005) (Abstract P1245).
36. Swart PJ, Oelen WE, Bruins AP, Tepper PG, de Zeeuw RA. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol. 18(2), 71-77 (1994).
37. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine. J. Clin. Pharmacol. 45(9), 1091 (2005) (Abstract 101).
38. Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa. 16th International Congress on Parkinson's Disease and Related Disorders, Berlin, Germany (2005) (Abstract 4775).
39. Hutton JT, Metman LV, Chase TN et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16(3), 459-463 (2001).
40. Bianchine J, Poole K, Woltering F. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson's disease. Neurology 58(Suppl. 3), A162-A163 (2002).
41. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. 60(12), 1721-1728 (2003). •• Only large trial of rotigotine in early PD published in manuscript form to date.
42. LeWitt PA, Nausieda PA, Chang F et al. Rotigotine transdermal system as adjunctive therapy to levodopa in patients with advanced-stage Parkinson's disease. Results of a randomized, double-blind, placebo-controlled, multicenter, multinational trial. 18th World Congress of Neurology Meeting, Sydney, Australia (2005) (Abstract). • Demonstrates that rotigotine appears efficacious in reducing off time in advanced PD patients.
43. Quinn N, for the SP511 Investigators. Rotigotine Transdermal Delivery System (TDS) (SP-962): a multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease. Parkinsonism Relat. Disord. 7(Suppl. 1), S66 (2002). • Study demonstrating that there was a pronounced placebo response in this trial of rotigotine versus placebo in advanced PD patients.
44. Giladi N, Tolosa E, Boothman B et al. Rotigotine transdermal system in patients with idiopathic Parkinson's disease: results of two placebo- and comparator controlled trials. Late Breaking Abstract presented at the World Parkinson Congress, Washington, DC, February (2006).
45. Poewe W, Giladi N, Boothman B et al. Rotigotine transdermal system in patients with advanced-stage Parkinson's disease as adjunctive therapy to levodopa: results of a placebo- and pramipexole-controlled trial. Late Breaking Abstract presented at the World Parkinson Congress, Washington, DC, February (2006).
46. Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J. Am. Acad. Dermatol. 37(2 Pt 2), 332-333 (1997).
47. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann. Pharmacother. 34(3), 382-385 (2000).
48. Leopold NA, Polanksy M, Hurka MR. Drug adherence in Parkinson's disease. Mov. Disord. 19(5), 513-517 (2004).
49. Bibbiani F, Constantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 192(1), 73-78 (2005).
50. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 23(Suppl. 10), S109-S115 (2000).
51. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23(10 Suppl.), S117-S126 (2000).
52. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000).
53. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61(7), 1044-1053 (2004).
54. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. 62(6), 905-910 (2005).
55. Lake Y, Pinnock S. Improved patient acceptability with a transdermal drug-inadhesive oestradiol patch. Aust. NZ J. Obstet. Gynaecol. 40(3), 313-316 (2000).
56. Stiasny-Kolster K, Kohnen R, Schollmayer E et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. 19(12), 1432-1438 (2004).
57. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural Transm. 111(10-11), 1375-1446 (2004).